Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies
Molecular pathophysiology of histone G34R mutated childhood brain tumours: towards the development of novel targeted therapies
Promoting physical activity in childhood cancer survivors: Using qualitative and co-design methods to inform the development of an evidence-based intervention
High-risk rhabdomyosarcoma patient derived 3D cultures to screen for novel drugs that enhance sensitivity to standard treatment
Epigenetic deregulation of splicing in childhood renal malignancies
Improving the diagnosis of children’s brain tumours by Functional Radiomics
Unravelling the impact of SMARCB1 loss on the chromatin landscape in malignant rhabdoid tumor to identify novel therapeutic opportunities
Comprehensive molecular characterization of paediatric spinal ependymomas
Developing leukaemic biomarkers to enable personalised CNS-directed therapy